India’s food regulator has initiated three adjudication cases against Nestlé India, citing alleged promotional misstatements and biotin standard violations in infant nutrition products, as the company affirms compliance and cooperation amid ongoing investigations.
India’s food regulator has opened three separate adjudication cases against Nestlé India over alleged breaches linked to infant nutrition products, including disputed promotional claims on e-commerce listings and a follow-up formula sample that allegedly failed to meet the required biotin standard.
According to reports from the Times of India and the Financial Express, the Food Safety and Standards Authority of India examined marketing material for NAN Excella Pro Stage 1 and Lactogen Pro 1 on online platforms. It objected to claims including “5 HMOs” and references to whey protein, as well as a statement that whey protein in Lactogen Pro 1 was easy to digest. The regulator said those assertions run afoul of rules that restrict promotional claims for infant foods.
The third case concerns a follow-up formula sample that was found to contain biotin below the prescribed level during laboratory testing. After the first result, the sample was sent for re-analysis at a referral laboratory, which also found it non-compliant, according to the reports.
Nestlé India has said its products comply with applicable rules. A company spokesperson said the relevant labels had been approved by an FSSAI expert committee and that the claims were backed by scientific literature. The company said it had already replied in detail to the regulator’s notice and would continue to cooperate with the authorities as the cases proceed.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
